Global cannabis company Tilray has been named as the supplier cannabis products for Luxembourg’s medical cannabis programme.
The firm has been selected by the Luxembourg Ministry of Health as a supplier of Good Manufacturing Practice (GMP) certified medical cannabis products for the country’s medical cannabis programme.
Tilray will supply a variety of its pharmaceutical-grade medical cannabis products, including extracts and dried flower with different levels of THC and CBD for patients with a range of medical conditions.
These prescription-based medical cannabis products will be administered to qualifying patients in Luxembourg under the supervision of physicians.
Tilray branded medical cannabis products are now available in 20 Countries around the world, as the firm continues to expand its footprint in Europe.
Irwin D. Simon, chairman and chief executive officer, at Tilray said: “We believe that Tilray’s growth potential in the European Union represents a $1 billion opportunity, and today’s announcement affirms that we are turning potential into performance. With today’s validation from the Luxembourg Ministry of Health, Tilray now offers branded medical cannabis in 20 countries around the world — a testament to our high standards and status as a trusted partner to patients in need. We’re proud to be building this unrivaled global platform and will continue to advocate for patient access in Europe and countries around the world.”
Tilray operates two state-of-the-art GMP-Certified cannabis cultivation facilities in Europe located in Cantanhede, Portugal, and Neumunster, Germany.
Denise Faltischek, head of international and chief strategy officer, added: “Tilray’s mission includes an unwavering conviction that patients around the world should have access to safe, high-quality cannabinoid-based medicine.
“We’re proud to expand this effort to Luxembourg and provide patients in need with pharmaceutical-grade medical cannabis products. We are committed to being a trusted partner, and we will continue to leverage our strong medical platform to increase access to the highest-quality medical cannabis for patients worldwide.”
Earlier this month Luxembourg announced that citizens would be able to cultivate cannabis at home for personal use in a move designed to keep users away from the black market.
[activecampaign form=31]
